Founded
Address
Pacific Horizon Ventures LLC
800 Fifth Avenue
Suite 4120
Seattle, WA 98104
United States
Phone
Website
Recent investment activity
KANDO id: 32303
Corporate information
Official name
Pacific Horizon Ventures Limited Liability Company
Registration country
Overview
We invest in early-stage in life science technologies that address significant healthcare problems in poorly served markets. These are opportunities that have the potential to change the societal healthcare equation. Most often, this means the development of products based on biotechnology or pharmaceutical chemistry but we are receptive to opportunities in medical devices, computational biology and genomics. We are active investors who take a hands-on role in the general management of portfolio companies during the early stages of development. The four principals of Pacific Horizon Ventures have worked together for over a decade and have accumulated an in-depth knowledge of the life sciences. We have a successful track record identifying and developing promising early-stage opportunities that have particular promise.Funding rounds
Investment preferences
Investment focus themes
Actual initial investment stage
N/A (1)
Investment activity status
Active investor
Selected investments
Displaying 26 - 32 of 32Company | Profile | Country | Funding | ||
---|---|---|---|---|---|
![]() |
Therion Biologics Corp | Developer of a therapeutic vaccines for cancer and preventive vaccines for AIDS. | N/A | ||
![]() |
Tissue Repair Company | Biopharmaceutical company with a clinical-stage focus on products that promote tissue repair. | N/A | ||
![]() |
TransMolecular Inc | TransMolecular is a biotechnology company. | N/A | ||
![]() |
Trimeris Inc | A biopharmaceutical company, engages in the development of a class of antiviral drug treatments. | N/A | ||
![]() |
ViaCyte Inc | N/A | |||
![]() |
VitaGen Inc | Biotechnology company focused on developing an artificial liver that would be used until a transplant is performed. | N/A | ||
![]() |
AtheroGenics Inc | N/A Initial investment |